期刊文献+

阿卡波糖对缺血性心脏病伴糖耐量异常患者的干预作用研究 被引量:2

Effect of acarbose on coronary atherosclerotic heart disease complicating impaired glucose tolerance
下载PDF
导出
摘要 目的探讨阿卡波糖对缺血性心脏病伴糖耐量异常患者的干预作用。方法收集缺血性心脏病伴糖耐量异常患者共187例,分为试验组(阿卡波糖干预组)97例;对照组90例,平均随访3.5年。观察其血糖及心血管事件的发生情况。结果187例患者,死亡6例,两组BMI、TG较治疗前均显著下降(P<0.05),试验组OGTT2h、HbA1c较治疗前均显著下降(P<0.05);急性心肌梗死发生率、新发生的心绞痛发生率及总的心血管事件发生率显著降低(P<0.05);试验组发展为DM数较对照组显著降低(P<0.05)。结论阿卡波糖对缺血性心脏病伴糖耐量异常患者进行干预,能有效降低心血管事件的发生及减少DM的发生率。 [ Objective ] To explore the effect of acarbose on coronary atherosclerotie heart disease complicating impaired glucose tolerance. [Methods ] 187 case patients with coronary atherosclerotie heart disease complicating impaired glucose tolerance were divided into two groups, test group 97 case was treated with acarbose, and other treatments were as same as the control group, to survey the BG levels in blood and new occurred cardiovascular event. [ Results ] Of 187 cases, 6 patients were dead, after treatment, the levels of BMI and TG of two groups were significantly lower than pretherapy. In test group, levels of OGTI" 2h, HbAle were significantly lower than pretherapy, incidence of acute myocardial infarction, angina pectoris, total cardiovascular event and diabetes were significantly lower than the control group's. [ Conclusions] Acarbose can reduce cardiovascular event and diabetes in patients with coronary atherosclerotic heart disease complicating impaired glucose tolerance.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2009年第19期3011-3013,共3页 China Journal of Modern Medicine
关键词 阿卡波糖 缺血性心脏病 糖耐量异常 糖尿病 acarbese coronary atherosclerotic heart disease impaired glucose tolerance diabetes
  • 相关文献

参考文献8

  • 1FUJISHIMA M, KIYOHARA Y, KATO I, et al. Diabetes and cardiovascular disease in prospective population survey in Japan: the H isayama study[J]. Diabetes, 1996, 45(Supp13): S14.
  • 2郭立萍,孙世伟.二甲双胍与阿卡波糖干预治疗糖耐量减低效果的比较[J].宁夏医学杂志,2007,29(8):732-733. 被引量:2
  • 3SHEN X, ZHENG S, THONGBOONKERD V, et al. Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes [J]. Am J Physiol Endocrinol Metab, 2004, 287: E896-E905.
  • 4LEBOWITZ HE. α-Glucosidase inhibitors as agents in the treatment of diabetes[J]. Diabetes Review, 1998, 6(2): 132.
  • 5CHIASSON JL. Aearbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial [J]. Endecr Pract, 2006, 12(Suppl 1): 25.
  • 6SHIMABUKURO M. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients:a randomized crossover study [J]. J Clin Endecrinol Metab, 2006, 91(3): 837.
  • 7AZUMA K. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitice blood glucose fluctuation [J]. Blochem Biophys Res Commun, 2006, 345(2): 688-693.
  • 8HEITZER T, SCHLINZIG T, KRONHN K, et al. Endothelial dysfunction oxidative stress, and risk of cardiovascular events in with coronary artery disease[J]. Circulation, 2001, 104: 2673-2678.

二级参考文献2

共引文献1

同被引文献22

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部